Navigation Links
Medarex to Present at the Jefferies Second Annual Healthcare Conference
Date:6/18/2008

PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Jefferies Second Annual Healthcare Conference at 11:15 a.m. Eastern Time on Wednesday, June 25, 2008. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at http://www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
2. Medarex to Present at the Bank of America 2008 Healthcare Conference
3. Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
5. Medarex to Receive Milestone Payment from Novo Nordisk
6. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
7. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
8. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex Announces Completion of Sale of Shares in Genmab A/S
11. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... CNA ... outlet had provided a research update on Aytu Bioscience and cited promising increases ... According to Soulstring, prescription rates for Natesto® have more than doubled since March ...
(Date:8/16/2017)... ... August 16, 2017 , ... Recent ... cell type. Many treatments for specific cancers, such as breast, prostate, or lung, ... is androgen deprivation therapy for advanced prostate cancer. , This therapy limits ...
(Date:8/16/2017)... , Aug. 16, 2017  This year,s edition of the Inc. ... in life sciences workforce solutions, has made the list for the third ... recognizes the nation,s fastest-growing private companies based on a set of quantitative ... which includes the fastest-growing companies in the Bay State ... Inc. 5000 ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , ... development, announces the launch of the new NHS Agile biosensor chip . ... data for a wide range of molecules, including small and large molecules, peptides, ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):